Home / Business and Economy / Gilead Buys Arcellx For $7.8B Cancer Push
Gilead Buys Arcellx For $7.8B Cancer Push
23 Feb
Summary
- Gilead acquired Arcellx for up to $7.8 billion.
- The deal aims to strengthen Gilead's cancer drug pipeline.
- Arcellx develops new immunotherapies for incurable diseases.
Gilead Sciences Inc. has agreed to acquire Arcellx Inc. for an equity value potentially reaching $7.8 billion. This acquisition is a key move to expand Gilead's presence in the cancer treatment sector.
The deal involves Gilead paying $115 per share in cash, with an additional $5 per share contingent on future sales performance. Arcellx is recognized for its development of novel immunotherapies targeting cancer and other intractable conditions.
This strategic acquisition is expected to strengthen Gilead's existing capabilities, particularly in oncology. The transaction is anticipated to conclude by the second quarter of 2026.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
